221 related articles for article (PubMed ID: 31455429)
61. Molecular Analysis of Elements of Melanoma Insensitivity to TCR-Engineered Adoptive Cell Therapy.
Jazirehi AR
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769156
[TBL] [Abstract][Full Text] [Related]
62. Early gastric cancer frequently has high expression of KK-LC-1, a cancer-testis antigen.
Futawatari N; Fukuyama T; Yamamura R; Shida A; Takahashi Y; Nishi Y; Ichiki Y; Kobayashi N; Yamazaki H; Watanabe M
World J Gastroenterol; 2017 Dec; 23(46):8200-8206. PubMed ID: 29290656
[TBL] [Abstract][Full Text] [Related]
63. TCRs genetically linked to CD28 and CD3ε do not mispair with endogenous TCR chains and mediate enhanced T cell persistence and anti-melanoma activity.
Govers C; Sebestyén Z; Roszik J; van Brakel M; Berrevoets C; Szöőr Á; Panoutsopoulou K; Broertjes M; Van T; Vereb G; Szöllősi J; Debets R
J Immunol; 2014 Nov; 193(10):5315-26. PubMed ID: 25320284
[TBL] [Abstract][Full Text] [Related]
64. Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope.
Cole DJ; Weil DP; Shamamian P; Rivoltini L; Kawakami Y; Topalian S; Jennings C; Eliyahu S; Rosenberg SA; Nishimura MI
Cancer Res; 1994 Oct; 54(20):5265-8. PubMed ID: 7522957
[TBL] [Abstract][Full Text] [Related]
65. Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells.
Chang CH; Wang Y; Li R; Rossi DL; Liu D; Rossi EA; Cardillo TM; Goldenberg DM
Cancer Res; 2017 Oct; 77(19):5384-5394. PubMed ID: 28819027
[TBL] [Abstract][Full Text] [Related]
66. Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice.
Maliar A; Servais C; Waks T; Chmielewski M; Lavy R; Altevogt P; Abken H; Eshhar Z
Gastroenterology; 2012 Nov; 143(5):1375-1384.e5. PubMed ID: 22819865
[TBL] [Abstract][Full Text] [Related]
67. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.
Morgan RA; Dudley ME; Yu YY; Zheng Z; Robbins PF; Theoret MR; Wunderlich JR; Hughes MS; Restifo NP; Rosenberg SA
J Immunol; 2003 Sep; 171(6):3287-95. PubMed ID: 12960359
[TBL] [Abstract][Full Text] [Related]
68. Aurora kinase A-specific T-cell receptor gene transfer redirects T lymphocytes to display effective antileukemia reactivity.
Nagai K; Ochi T; Fujiwara H; An J; Shirakata T; Mineno J; Kuzushima K; Shiku H; Melenhorst JJ; Gostick E; Price DA; Ishii E; Yasukawa M
Blood; 2012 Jan; 119(2):368-76. PubMed ID: 22025529
[TBL] [Abstract][Full Text] [Related]
69. Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer.
Kobold S; Steffen J; Chaloupka M; Grassmann S; Henkel J; Castoldi R; Zeng Y; Chmielewski M; Schmollinger JC; Schnurr M; Rothenfußer S; Schendel DJ; Abken H; Sustmann C; Niederfellner G; Klein C; Bourquin C; Endres S
J Natl Cancer Inst; 2015 Jan; 107(1):364. PubMed ID: 25424197
[TBL] [Abstract][Full Text] [Related]
70. Engineering antigen-specific NK cell lines against the melanoma-associated antigen tyrosinase via TCR gene transfer.
Parlar A; Sayitoglu EC; Ozkazanc D; Georgoudaki AM; Pamukcu C; Aras M; Josey BJ; Chrobok M; Branecki S; Zahedimaram P; Ikromzoda L; Alici E; Erman B; Duru AD; Sutlu T
Eur J Immunol; 2019 Aug; 49(8):1278-1290. PubMed ID: 31054264
[TBL] [Abstract][Full Text] [Related]
71. Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes.
Zhou X; Li J; Wang Z; Chen Z; Qiu J; Zhang Y; Wang W; Ma Y; Huang N; Cui K; Li J; Wei YQ
Neoplasia; 2013 May; 15(5):544-53. PubMed ID: 23633926
[TBL] [Abstract][Full Text] [Related]
72. T cell-receptor V gene use by CD4+ melanoma-reactive clonal and oligoclonal T-cell lines.
Nishimura MI; Custer MC; Schwarz SL; Parker LL; Mixon A; Clay TM; Yannelli JR; Rosenberg SA
J Immunother; 1998 Sep; 21(5):352-62. PubMed ID: 9789197
[TBL] [Abstract][Full Text] [Related]
73. Preclinical Characterization of HPN536, a Trispecific, T-Cell-Activating Protein Construct for the Treatment of Mesothelin-Expressing Solid Tumors.
Molloy ME; Austin RJ; Lemon BD; Aaron WH; Ganti V; Jones A; Jones SD; Strobel KL; Patnaik P; Sexton K; Tatalick L; Yu TZ; Baeuerle PA; Law CL; Wesche H
Clin Cancer Res; 2021 Mar; 27(5):1452-1462. PubMed ID: 33262134
[TBL] [Abstract][Full Text] [Related]
74. Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo.
de Jong G; Bartels L; Kedde M; Verdegaal EME; Gillissen MA; Levie SE; Cercel MG; van Hal-van Veen SE; Fatmawati C; van de Berg D; Yasuda E; Claassen YB; Bakker AQ; van der Burg SH; Schotte R; Villaudy J; Spits H; Hazenberg MD; van Helden PM; Wagner K
Cancer Immunol Immunother; 2021 Jun; 70(6):1569-1581. PubMed ID: 33225419
[TBL] [Abstract][Full Text] [Related]
75. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors.
Yang M; Tang X; Zhang Z; Gu L; Wei H; Zhao S; Zhong K; Mu M; Huang C; Jiang C; Xu J; Guo G; Zhou L; Tong A
Theranostics; 2020; 10(17):7622-7634. PubMed ID: 32685008
[No Abstract] [Full Text] [Related]
76. T-cell receptor gene therapy in human melanoma-bearing immune-deficient mice: human but not mouse T cells recapitulate outcome of clinical studies.
Straetemans T; Coccoris M; Berrevoets C; Treffers-Westerlaken E; Scholten CE; Schipper D; Ten Hagen TL; Debets R
Hum Gene Ther; 2012 Feb; 23(2):187-201. PubMed ID: 21958294
[TBL] [Abstract][Full Text] [Related]
77. Induction of antitumor cytotoxic lymphocytes using engineered human primary blood dendritic cells.
Wu L; Zhang H; Jiang Y; Gallo RC; Cheng H
Proc Natl Acad Sci U S A; 2018 May; 115(19):E4453-E4462. PubMed ID: 29674449
[TBL] [Abstract][Full Text] [Related]
78. A High-Avidity T-cell Receptor Redirects Natural Killer T-cell Specificity and Outcompetes the Endogenous Invariant T-cell Receptor.
Landoni E; Smith CC; Fucá G; Chen Y; Sun C; Vincent BG; Metelitsa LS; Dotti G; Savoldo B
Cancer Immunol Res; 2020 Jan; 8(1):57-69. PubMed ID: 31719055
[TBL] [Abstract][Full Text] [Related]
79. Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells.
Iwahori K; Kakarla S; Velasquez MP; Yu F; Yi Z; Gerken C; Song XT; Gottschalk S
Mol Ther; 2015 Jan; 23(1):171-8. PubMed ID: 25142939
[TBL] [Abstract][Full Text] [Related]
80. Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor.
Zhang G; Wang L; Cui H; Wang X; Zhang G; Ma J; Han H; He W; Wang W; Zhao Y; Liu C; Sun M; Gao B
Sci Rep; 2014 Jan; 4():3571. PubMed ID: 24389689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
